








DANISH VALIDATION OF THE MERLIN TEST

Marie Brinch-Møller Weitemeyer MD, PhD student

Department of Plastic Surgery Copenhagen University Hospital – Herlev and Gentofte, Herlev, DK







METHOD

RESULTS

Unpublished data



*Inclusion criteria

- First-time invasive cutaneous melanoma (T1-T3)
- Age ≥18 yr
- SLNB ≤90 days from primary biopsy
- No additional metastasis ≤90 days from primary biopsy
- Full histopathological report available
- \geq 5 yr follow up

Melanoma & sentinel node biopsy



tumor tissue



Merlin test





HIGHLY PRECISE in **DETECTING** melanoma patients **WITHOUT** sentinel node **METASTASIS**



Potentially LARGE REDUCTION in SENTINEL LYMPH NODE BIOPSIES



CONSISTENT with findings in previous **VALIDATION STUDIES**

PROMISING tool to **DESELECT** melanoma patients from **SENTINEL NODE BIOPSY**

FLANO

ESPECIAI

Need for comparison to other prediction tools, further prospective validation and cost-effectiveness analyses **TO BE CONTINUED...**



Study group

Marie B. Weitemeyer¹, Neel M. Helvind¹, Annette H. Chakera¹, Siri Klausen², Erik Clasen-Linde², Grethe Schmidt³, Lisbet R. Hölmich¹

¹Department of Plastic Surgery, Copenhagen University Hospital – Herlev and Gentofte, Herlev, DK ²Department of Pathology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, DK ³Department of Plastic Surgery and Burns Treatment, Copenhagen University Hospital – Rigshospitalet, Copenhagen, DK

Acknowledgements

Department of Pathology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, DK Department of Pathology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, DK

Funded by



See you at

POSTER "VI"



